Resvent

Based in Shenzhen, China, Resvent Medical Technology Co. specializes in innovative respiratory health solutions, focusing on the diagnosis and treatment of chronic respiratory diseases through advanced technology and artificial intelligence. Founded in 2015 in Shenzhen, China, Resvent Medical Technology Co. develops advanced respiratory health solutions.

The company has successfully engaged in one funding deal as of December 2025, indicating an ongoing commitment to enhance its operational capabilities and market presence. Resvent specializes in providing advanced respiratory health solutions, focusing on the diagnosis and treatment of chronic respiratory diseases, including both invasive and non-invasive mechanical ventilation. Their flagship product, the EIT-iNueview medical device, is designed for comprehensive respiratory monitoring and management and has recently received regulatory approval. The company primarily serves healthcare providers, hospitals, and clinics, with clients in major urban centers across China and select international markets.

Resvent's revenue model is based on direct sales of medical devices and subscription services for digital health solutions. Engaging in B2B transactions, it collaborates with hospitals and healthcare institutions to supply innovative respiratory health technologies, with clients purchasing equipment such as the EIT-iNueview under customized contractual agreements that may include service plans for maintenance and upgrades. In December 2025, Resvent raised an undisclosed amount of Series B+ funding from new investor Cofoe. This financing will be utilized to strengthen technological R&D, expand product lines, and broaden market reach.

The company plans to introduce new products and expand into additional international markets, although specific regions have not been disclosed.